Mizuho Maintains Outperform on Vaxcyte, Raises Price Target to $163
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Salim Syed has maintained an 'Outperform' rating on Vaxcyte (NASDAQ:PCVX) and raised the price target from $113 to $163.
September 10, 2024 | 1:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho analyst Salim Syed has maintained an 'Outperform' rating on Vaxcyte and increased the price target from $113 to $163, indicating strong confidence in the company's future performance.
The increase in the price target from $113 to $163 by Mizuho suggests a strong positive outlook for Vaxcyte. The 'Outperform' rating indicates that the analyst expects the stock to perform better than the market average, which is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100